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ABSTRACT
Objective: Glutathione S-transferase mu 1 (GSTM1) and GST theta 1 (GSTT1) genes are two xenobiotic metabolizing genes in Phase II of the detoxification 
process. The polymorphisms of GSTM1, GSTT1 genes, and smoking are involved in many cancers such as bladder cancer. Our aim was to assess the role 
of smoking status and GSTM1 and GSTT1 null genotypes in bladder cancer development in Algerian population.
Methods: The current case–control study included 175 bladder cancer patients and 188 controls matched for age, gender, and ethnic origin. The 
GSTM1 and GSTT1 genotypes were determined by multiplex polymerase chain reaction using blood genomic DNA. Possible associations of stage and 
grade with the obtained genotypes were also tested.
Results: A significant associations were observed between bladder cancer risk and tobacco smoke (p value: p=1.21E-08), GSTM1 null genotype 
(p=0.018), GSTT1 null genotype (p=0.009), and GSTM1/GSTT1-double null genotype (p=0.001). The combined effect of smoking and testing deletions 
increased the risk of bladder cancer and the most important risk was observed among smokers carrying GSTM1/GSTT1-double null genotype 
(p=1.09E-05). No significant association was shown between stage and grade of bladder cancer and the testing genotypes.
Conclusion: This study indicated that smoking, GSTM1 null, GSTT1 null, and GSTM1/GSTT1-double null genotypes individually represent a risk factor 
for bladder cancer in Algerian population. The interaction smoking gene increased the risk considerably. In fact, it is suggested that patients with 
cigarette smoking habit and combined GSTM1 and T1 genes deletion might be at increased risk of bladder cancer.
Keywords: Glutathione S-transferase mu 1, Glutathione S-transferase theta 1, Smoking, Bladder cancer.
INTRODUCTION
Cancer is currently estimated to be a major cause of deaths worldwide 
[1]. Urothelial bladder cancer is one of the commonly occurring cancers 
[2]. It is the 7th most commonly diagnosed cancer in males and the 17th in 
females worldwide. Global estimates suggest that there are annually 330–
400 bladder cancer cases with 123,100 related deaths in the word [3].
In North African men, bladder cancer is the most common cancer after 
liver and lung cancers, accounting an annual estimated incidence of 
11,225 with 5489 deaths [3]. Between 2006 and 2010, the incidence for 
Algerian men were 10.3/100,000 person-years, this represents 9.1% of 
the global cancer incidence in Algeria [4].
Bladder cancer can be muscle-invasive or non-invasive and classified as 
high-grade or low-grade tumor, respectively [5]. The risk of this disease 
increases with advancing age and most cases are diagnosed above 
65 years of age [6]. The incidence is 5–7 times higher in males than in 
females in Algeria and North Africa [3,4].
It is admitted that the primary prevention of this deadly disease needs 
first of all understanding the etiology and determining the risk factors.
Smoking is the most well-established risk factor for bladder cancer 
in both sexes [5,7], with the risk among smokers reported to be 
approximately fourfold that among non-smokers [7].
The combustion of tobacco releases at least at 69 known carcinogens 
which have been directly implicated as mutagens causing bladder 
cancer [8,9].
Following smoking, occupational exposure to aromatic amines and 
polycyclic aromatic hydrocarbons (PAHs) are other important risk 
factors [10]. Increasing evidence suggests a significant influence of 
genetic polymorphism of xenobiotic-metabolizing enzymes which 
could increase susceptibility to various environmental and clinical 
conditions. The balance between activation and detoxification of 
carcinogens affects the amount of DNA damage that occurs in cells [11].
A large family of enzymes has been encoded by glutathione-S-
transferases (GSTs) multigene and plays a vital role in the mechanism 
of cellular detoxification [9,12]. Until now, human cytosolic GST 
superfamily contains at least 16 genes subdivided into eight distinct 
classes designated as: (pi), (alpha), (sigma), (mu), (theta), (kappa), 
(omega), and (zeta), which are encoded by the GSTA, GST mu (GSTM), 
GSTK, GSTO, GSTP, GSTS, GST theta (GSTT), and GSTZ genes [11]. They 
catalyze different reactions with bladder cancer carcinogens such as 
aminobiphenyls and PAHs [13]. Functional polymorphisms have been 
identified in the GSTM1, GSTT1, GSTP1, and GSTA1 [11,14]. In recent 
years, studies of GSTs have revealed new roles for some of the members 
of this family. It has been demonstrated that GSTs of classes (alpha), (mu), 
and (pi) are involved in cell proliferation, differentiation, and control of 
cell death through interactions with special signaling proteins [15].
It was reported that both GSTM1 and GSTT1 genes exhibit deletion 
polymorphisms. Homozygous deletions of these genes resulted in 
null genotypes which results in a lack of enzyme activity [9,12]. This 
information suggests that these mutations may interfere and affect the 
susceptibility to many malignant tumors as cervical, laryngeal, oral, and 
bladder cancer [9,12].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Positive association of GSTM1 and GSTT1 deletion polymorphism and 
bladder carcinoma was found among many populations [16]. However, 
data related to a genetic status of GSTM1 and GSTT1 and their association 
to bladder cancer is not available in Algerian population. Therefore, the 
aim of this current study was first to examine the association between 
GSTM1 and GSTT1 genes variants and bladder cancer risk through a 
case–control study in Algerian population. Then, we evaluated the 
differential as well as the combined effect of selected variants according 
to tobacco smoking in the onset and development of bladder carcinoma. 
Finally, we tried to establish an association between these two studied 
genes and clinicopathologic characteristics of bladder cancer.
METHODS
Subjects
The study population consisted of 175 patients with bladder cancer and 188 
healthy controls. Cases were recruited between September 2014 and May 
2016 from Central Hospital University of Tizi-Ouzou (Urology department) 
and Daksi renal Clinic of Constantine (Urology department). All were from 
North of Algeria, aged between 22 and 90 years. More than 92% of them 
were men. All patients were confirmed by clinical histopathology and 
staged according to the tumor/node/metastasis staging system of the 
Union International Contre le Cancer (UICC; 1997). Tumors were graded 
according to the World Health Organization 1973 classification.
The control group consisted of unrelated healthy subjects without a 
history of malignant disease who were approximately matched for 
gender proportion, geographic origin, and age range, to those in the 
case group. A detailed questionnaire was elaborated and used to obtain 
study information’s, and under informed consent, peripheral blood 
samples were collected into tubes with EDTA (pH 8).
DNA extraction
Genomic DNA was extracted from peripheral leukocytes using 
sodium chloride (NaCl) method. The quality and quantity of DNA 
were determined, respectively, by agarose gel electrophoresis and 
spectrophotometric analysis using nanodrop. DNA was diluted to 
10 ng/ml and stored at −20°C for further use as a template.
Genotyping of the GSTM1 and GSTT1 using multiplex polymerase 
chain reaction (PCR)
The screening of GSTM1 and GSTT1 genes was performed by multiplex 
PCR methodology. Briefly, the PCR was carried out in 25 µl mixture 
containing 50 ng of DNA using DNA Polymerase Kit: HotStarTaq 
DNA polymerase-QIAGEN (4 µl buffer ×1, 8 mM of deoxynucleosides 
S-triphosphates, 2 U/µl Taq polymerase, and 2.5 mM of each primer).
The paired primers for GSTM1 were:
5’-GAACTCCCTGAAAAGCTAAAGC-3’ and 5’-GTTGGGCTCAAATATACGGT 
GG-3’ [12].
The paired primers for GSTT1 were:
5’-TTCCTTACTGGTCCTCACATCTC-3’ and 5’-TCACCGGATCATGGCCACCA- 
3’ [12].
The paired primers for β-globulin were:
5’-ACACAACTGTGTTCACTAGC-3’ and 5’-CAACTTCATCCACGTTCACC- 
3’ [12].
β-globulin was used as an internal control, confirming successful PCR 
amplification to ensure that the GSTM1 null and GSTT1 null were due to 
the deletion allele of the GSTs and not because of the failure of the PCR.
Cycling  conditions  were  as  follows:  Initial  preheat  95°C  for  10  min, 
35 cycles of 94°C for 1 min, 60°C for 45 s, and 72°C for 1 min. The final 
extension was done at 72°C for 10 min. The amplified products were 
subjected to electrophoresis on 2% agarose gel, stained with ethidium 
bromide, and visualized under ultraviolet light. The GSTM1 fragment 
was 230 bases pairs (bp), the GSTT1 was 480 bp, and the β-globulin 
fragment was 110 bp in size.
Statistical analysis
Relative risks were estimated by calculating the odds ratios (OR) with 
95% confidence intervals (CI) at the 0.05 significance level. OR were 
calculated using R software version 3.2.3. p<0.05 were considered 
statistically significant.
RESULTS
Characteristics of the study population
Relevant characteristics of cases and controls are given in Table 1. 
There are more male than female cases (92.6% vs. 7.4%) with a sex 
ratio of 12:1. The mean age of bladder cancer patients and controls 
were similar, 60.77±13.21 years (range 22–90) and 59.56±14.02 years 
(range 22–89), respectively. 80% of bladder cancer patients were more 
than 50 years of age. Smoking was more widespread among patients 
with bladder cancer 122/175 (69.7%) than controls 74/188 (39.4%) 
which it recalled that they had been taken randomly (p=1.21E-08). Of 
the 175 cancer patients, 16% had tumors with Grade I, 25.1% Grade II, 
and 58.9% Grade III. 19.4% had a Ta stage, 48.6% had a T1, 23.4% had 
a T2, and 8.6% had a T3 stage or more.
GSTs genotypes, bladder cancer susceptibility, and interactions 
with smoking
GSTs genotypes frequencies and their relation to bladder cancer 
risk
GSTM1 null genotype (M1-) was more frequent than GSTT1 null 
genotype (T1−). Their frequencies were 57.1% and 39.4%, respectively, 
in bladder cancer patients compared to 44.7% and 26.6% respectively in 
healthy controls (Table 2). These results show a significant association 
between the GSTM1 null genotype and risk of bladder cancer (p=0.018). 
GSTT1 null genotype was also associated with greater risk toward this 
type of cancer (p=0.009).
Combined GSTM1 and GSTT1 genotypes and bladder cancer risk
The analysis of combined GSTM1 and GSTT1 genotypes revealed that 
all combinations were significantly associated with increased bladder 
cancer risk. As presented in Table 2, our results show clearly that the 
combinations between GSTM1 and GSTT1 genotypes increase the OR 
values and decrease the p value. The highest OR was observed for 
GSTM1/GSTT1-double null genotype (OR=2.9; CI: 1.44–6; p=0.001).
Association of GSTs genotypes and smoking status with bladder 
cancer risk
The stratification of patients and controls according to GSTs genotypes 
and tobacco status is depicted in Table 2. The results indicated any 
statistically significant association between GSTM1 null, GSTT1 null 
genotypes, or possible combined GSTM1/GSTT1 genotypes with 
bladder cancer risk among never smoker group.
However, among current or prior smokers group, all tested genotypes 
were revealed as risk genotypes except for combined GSTM1 positive/
GSTT1 positive (p=0.17).
It is important to note that the interaction of smoking and one GSTs 
null genotypes increase the risk considerably, (OR=6.7; CI: 2.8–16.8; 
p=1.33E-06) for GSTM1 null genotype and (OR=6.9; CI: 2.3-22.7; 
p=0.0001) for GSTT1 null genotype. Smokers with GSTM1/GSTT1-double 
null genotypes have a most important risk for developing bladder cancer 
(OR=7.9; CI: 2.8–24.4; p=1.09E-05) when compared to a reference group 
of non-smokers with the GSTM1 positive/GSTT1 positive.
Relationship between GSTs genotypes and clinicopathological 
parameters 
The associations of GSTM1, GSTT1, or combined GSTM1/GSTT1 
genotypes with tumor grades or stages of bladder cancer were not seen 
(data not shown).
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Table 1: Characteristics of the study population
Parameters Controls (%) Cases (%) OR CI p value
Gender
Male 169 (89.9) 162 (92.6) - - 0.37
Female 19 (10.1) 13 (7.4) - -
Age (years)
<50 43 (22.9) 35 (20) - - 0.5
≥50 145 (77.1) 140 (80) - - -
Mean age (range) 59.56±14.02 (22–89) 60.77±13.21 (22–90) - - -
Smoking status
Never smoker 114 (60.6) 53 (30.2) - - -
Current or prior smoker 74 (39.4) 122 (69.7) 3.55 229–5.48 1.21E-08**
Grade
G1 - 28 (16) - - -
G2 - 44 (25.1) - - -
G3 - 103 (58.9) - - -
TNM stage
Ta - 34 (19.4) - - -
T1 - 85 (48.6) - - -
T2 - 41 (23.4) - - -
T3 or more - 15 (8.6) - - -
Recurrences
No - 83 (47.4) - - -
Yes - 92 (52.6) - - -
Cystectomy after 
Evolution
- 9 (5.1) - - -
**: P<0.01. TNM: Tumor/node/metastasis, OR: Odds ratios, CI: Confidence intervals
Table 2: GSTM1, GSTT1 genotypes, and combined genes‑smoking effect on bladder cancer susceptibility
Genotypes Controls (%) Cases (%) OR CI 95% p value
GSTM1
M1+ 104 (55.3) 75 (42.9) - - -
M1− 84 (44.7) 100 (57.1) 1.65 1.09–2.5 0.018
GSTT1
T1+ 138 (73.4) 106 (60.6) - - -
T1− 50 (26.6) 69 (39.4) 1.8 1.15–2.8 0.009**
GSTM1/GSTT1
M1+/T1+ 76 (40.4) 40 (22.9) - - -
M1+/T1− 28 (14.9) 35 (20) 2.36 1.2–4.67 0.004**
M1-/T1+ 62 (33) 66 (37.7) 2.02 1.2–3.39 0.007**
M1‑/T1− 22 (11.7) 34 (19.4) 2.9 1.44–6 0.001**
GSTM1-smoking
Never smoker
M1+ 58 (30.9) 28 (16) - - -
M1− 56 (29.8) 25 (14.3) 0.9 0.45–1.86 0.87
Current or prior smoker
M1+ 46 (24.5) 47 (26.9) 2.1 1.1–4.1 0.01**
M1− 28 (14.9) 75 (42.9) 5.5 2.84–10.9 3.87E-08**
GSTT1-smoking
Never smoker
T1+ 81 (43.1) 31 (17.7) - - -
T1− 33 (17.6) 22 (12.6) 1.7 0.8–3.6 0.1
Current or prior smoker
T1+ 57 (30.3) 75 (42.9) 3.4 2–6 6.96E-06**
T1− 17 (9) 47 (26.9) 7.1 3.4–15.4 6.3E-09**
GSTM1/GSTT1-smoking
Never smoker
M1+/T1+ 38 (20.2) 14 (8) - - -
M1+/T1− 20 (10.6) 14 (8) 1.88 0.7–5.2 0.2
M1-/T1+ 43 (22.9) 18 (10.3) 1.1 0.5–2.8 0.8
M1‑/T1− 13 (6.9) 7 (4) 1.4 0.4–5 0.56
Current or prior smoker
M1+/T1+ 38 (20.2) 26 (14.9) 1.8 0.8–4.4 0.17
M1+/T1− 8 (4.3) 21 (12) 6.9 2.3–22.7 0.0001**
M1-/T1+ 19 (10.1) 48 (27.4) 6.7 2.8–16.8 1.33E-06**
M1‑/T1− 9 (4.8) 27 (15.4) 7.9 2.8–24.4 1.09E-05**
GSTM1 positive (M1+), GSTM1 null (M1−), GSTT1 positive (T1+), and GSTT1 null (T1−), (**): P<0.01. GSTM1: Glutathione S-transferase mu 1, GSTT1: Glutathione 
S-transferase theta 1, OR: Odds ratios, CI: Confidence intervals
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DISCUSSION
We have undertaken this current study to investigate the combined 
effect of GSTM1, GSTT1 genes polymorphism, and smoke on bladder 
cancer susceptibility in Algerian population.
Our case–control study revealed, first in bladder cancer group 
that the incidence is 12 times higher in males than in females 
(sex ratio 12:1). This difference in incidence is greater than those 
reported in previous studies among North Africans [3] and Algerian 
population [4]. We have also shown that cigarette smoking was a 
significant risk factor for bladder cancer risk (OR=3.55; CI: 2.9–5.48; 
p=1.21E-08). More than 50% of our cases are smokers. A similar 
observation was made by Burger et al. [8]. Several previous studies 
in the world demonstrated the increased risk of bladder cancer in 
smokers [5,7,16,17].
Bladder cancer is the result of the variable combination of two 
determinants: Endogenous or constitutional factors and exogenous or 
environmental factors [6]. Genetic differences between detoxification 
systems may cause an increase in susceptibility to environmentally 
induced bladder cancer [18]. Thus, the GSTs are multigene family-
related isozymes that involved in the detoxification of carcinogens, 
including PAHs present in tobacco smoke [6,9,12,19]. It was noted that 
GSTM1 null genotype is the most important factor for the reduction 
of total GST activity [20]. The polymorphism in the GSTT1 gene loci is 
also caused by a gene deletion and leads to a virtual absence of enzyme 
activity in individuals with the null genotype [11]. GSTM1 and GSTT1 
gene polymorphisms have been associated with a wide variety of 
cancers including bladder cancer [9].
It is reported that the prevalence of GSTM1 null genotype varies widely 
from 31% to 88% in relation to ethnic origin [21]. This frequency in our 
studied population was 44.7% for healthy controls and 57.1% for cases 
which approach substantially to that given for Tunisian and Egyptian 
populations [22-24]. Deletion of GSTT1 loci was higher in bladder 
cancer patients than in controls (39.4% vs. 26.6%, respectively). 
These proportions were so different to that compared to other ethnic 
groups [25].
To investigate the impact of metabolic polymorphism in modulating 
bladder cancer risk susceptibility, we have compared genotypic 
frequencies of studied genes between individuals carrying the wild-
type (GSTM1 positive, GSTT1 positive) and individuals at risk (GSTM1 
null, GSTT1 null).
Our results indicate that in Algerian population the GSTM1 null genotype 
confers statistically a significant correlation for overall risk for bladder 
cancer (OR=1.65; CI: 1.09–2.5; p=0.018). This finding is consistent 
with combined results of 26 studies represented in the meta-analysis 
of Zhang et al. [26], including 5029 bladder cancer cases and 6680 
controls. Other more recent studies carried out in India and Pakistan 
have given the same result [16,27]. Among all studied ethnic groups, the 
association between GSTM1 null genotype and risk of bladder cancer 
was observed in Asians and Caucasians [26]. Conversely, in Tunisian 
and Egyptian populations results suggested that this polymorphism 
had no effect on risk of bladder carcinogenesis [24,28-30]. Moreover, 
only one Egyptian study recorded this association, but it presented a 
limitation of effective which was too low [31].
We also investigated the association of GSTT1 and bladder cancer. 
As for the GSTM1 null genotype, statistical test shows an association 
between the GSTT1 null genotype and urinary bladder cancer (OR=1.8, 
CI: 1.15–2.8; p=0.009). Our results were in agreement with a number 
of other studies presented in a meta-analysis of Gong et al. [19] who 
reported this association in Caucasians. However, no dramatically 
increased risk was found for other populations including North 
Africans [12,19,24,28,29,32], except for the study of Saad et al. [30] who 
suggested an increased risk with GSTT1null genotype in the Egyptian 
population.
Patients with combined homozygous deletion (GSTM1 null/GSTT1 
null) have a greater risk (OR=2.9; CI: 1.44–6; p=0.001) compared to 
those harboring only one deletion. This is in accordance to the results 
mentioned in the meta-analyses of Gong et al. [19]. This observation can 
be explained by the fact that the presence of the combined homozygous 
deletion of GSTM1 and GSTT1 genes is associated with reduction or 
complete loss of the enzyme activity [12,13]. In this context, we can 
suggest that the double mutated genotype may play an important role 
in the susceptibility of bladder cancer.
In this study, we have also compared genotypic frequencies of studied 
genes combined with smoking status between non-smokers carrying 
wild type as a reference group and individuals at risk: Smokers with 
one or two genetic risk factors. About GSTM1 null genotype, we found 
that risk is present only in smokers. However, for GSTT1 null genotype, 
the risk is most important in smokers than no smokers group.
The simultaneous association of both null GSTM1 and GSTT1 genotypes 
with cigarette smoke status gives a highest probability to develop 
bladder cancer.
This combination smoking gene is biologically plausible because GSTM1 
and GSTT1 genes are involved in Phase II detoxification of carcinogens 
PAHs found in cigarette smoke. Anyone of the two null GSTM1 or GSTT1 
genotypes causes reductions of enzymatic activity [12,13].
Among non-smokers group, the exposure to these carcinogens is much 
less important than in smokers group. Therefore, the null genotypes 
of GSTM1 and GSTT1 genes will have a less dangerous effect on non-
smokers group. However, in smokers, continuous exposure makes 
the process of detoxification that involves interventions of enzymes 
encoded by GSTM1 and (or) GSTT1 genes very important. Rouissi 
et al. [29] have noted an increased risk after the combination of many 
factors including GSTM1 null, GSTT1 null genotypes, and smoking. We 
concluded that the simultaneous association of risk factors gives a high 
probability to develop bladder cancer as shown by increased OR value 
presented in our study (OR=7.9).
On the other hand, the results of this current study indicate that there 
were no statistically significant associations between the clinical stages 
and histological grades of tumors and the frequencies of genotypes. Our 
findings concur with many previously published studies [11,20,32].
CONCLUSION
In conclusion, our data suggest in Algerian population that GSTM1 
null and GSTT1 null genotypes increase the risk for urinary bladder 
carcinoma. The combination of the two gene polymorphisms 
represents a greater risk. A strong association was found between 
genetic deletions of GSTM1, GSTT1, and bladder cancer among smokers. 
The most important risk was shown in smokers carrying double 
deletions of studied genes. An absence of association between GSTs 
genotypes, stage, and grade of tumors was registered. However, owing 
to the relatively smaller sample size, further studies on larger series of 
patients are required to confirm the present findings.
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